Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index in Patients with Colorectal Cancer

• Published in: Gastroenterology research and practice Vol. 2020; no. 2020; pp. 1 - 8
• Main Authors: Jiang, Xiaohui, Qian, Hongyan, Zhao, Wenjing, Chen, Xin, Zhang, Xunlei, Shao, Jingjing, Li, Jing, Cui, Xiaopeng
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2020; Hindawi; Hindawi Limited; Wiley
• Subjects: Biomarkers; Colorectal cancer; Confidence intervals; Ethnicity; Inflammation; Lymphocytes; Medical prognosis; Neutrophils; Surgery; Survival analysis; Tumors; Italy; China; Europe
• ISSN: 1687-6121; 1687-630X
• DOI: 10.1155/2020/8781674

Background. Multiple studies have reported the significance of the systemic immune-inflammation index (SII) in the prognosis of colorectal cancer (CRC), but no consensus has yet been reached. The purpose of this study was to systematically assess the prognostic value of SII in patients with CRC. Materials and Methods. We performed a systematic literature search in PubMed, Embase, and the Cochrane Library for eligible studies. The correlation between pretreatment SII and overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in CRC patients was evaluated by combining the hazard ratio (HR) and 95% confidence interval (CI). Results. Twelve studies involving 3919 patients were included. Comprehensive analysis results showed that high SII indicated poor OS in CRC patients (HR=1.777, 95% CI: 1.328-2.376). Compared with patients with low SII values, patients with high SII had lower PFS (HR=1.658, 95% CI: 1.189-2.311). Subgroup analysis further verified the above results. Conclusions. SII may be a noninvasive and powerful tool for predicting survival outcomes in CRC patients. However, more well-designed studies are needed to validate our findings.